Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] - N0000175623

Pharmacologic Code	N0000175623
Pharmacologic Name	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Pharmacologic Uses	respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor RSV anti-F protein monoclonal (mAb)
Pharmacologic Concept	Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description	An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions: A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication. A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

The table contains 4 products whose active ingredient are classified under the same pharmacologic class Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	49281-574	Beyfortus	Non-Proprietary Name: Nirsevimab	Injection	Intramuscular	Sanofi Pasteur Inc.	ACTIVE
	49281-575	Beyfortus	Non-Proprietary Name: Nirsevimab	Injection	Intramuscular	Sanofi Pasteur Inc.	ACTIVE
	66658-230	Synagis	Non-Proprietary Name: Palivizumab	Injection, Solution	Intramuscular	Swedish Orphan Biovitrum Ab (publ)	ACTIVE
	66658-231	Synagis	Non-Proprietary Name: Palivizumab	Injection, Solution	Intramuscular	Swedish Orphan Biovitrum Ab (publ)	ACTIVE